Defects of mismatch repair are thought to be responsible for carcinogenesis in hereditary non-polyposis colorectal cancer and about 15% of sporadic colon cancers. The phenotype is seen as microsatellite instability and is known to be caused either by mutations in mismatch repair genes or by aberrant methylation of these genes stabilizing their downregulation. Lack of repair of microsatellite sequence errors, created during replication, leads to a mutation-prone phenotype. Where mutations occur within mononucleotide tracts within exons they cause translation frameshifts, premature cessation of translation and abnormal protein expression. Such mutations have been observed in the TGFbRII, BAX, IGFIIR, MSH3 and MSH6 genes in colon and other cancers. We describe here frameshift mutations aecting the gene for the methyl-CpG binding thymine glycosylase, MBD4, in over 40% of microsatellite unstable sporadic colon cancers. The mutations all appear heterozygous but their location would ensure truncation of the protein between the methyl-CpG binding and glycosylase domains, thus potentially generating a dominant negative eect. It is thus possible that such mutations enhance mutation frequency at other sites in these tumours. A suggestion has been made that MBD4 (MED1) mutations may lead to an increased rate of microsatellite instability but this mechanism appears unlikely due to the nature of mutations we have found.
Keywords: MBD4; colorectal cancer; RER; mismatch repair MBD4 was identi®ed as a methyl-CpG binding protein related to the transcriptional repressor MeCP2 and containing a C-terminal domain homologous to DNA repair proteins (Hendrich and Bird, 1998) . It has been demonstrated that the protein can bind to methylCpG/TpG and to symmetrically methylated CpG, and also has the ability to remove Thymine (T) or Uracil (U) from mismatched CpG sites (Hendrich and Bird, 1998; Hendrich et al., 1999a) . Transition mutation of methyl-Cytosine (methyl-C) to T at CpG dinucleotide sites occurs at elevated rates in mammals and accounts for a disproportionately high frequency of point mutations in human cancers (for example within p53 (Rideout et al., 1990) ) and genetic diseases (Bird, 1980; Cooper and Youssou®an, 1988; Rideout et al., 1990; Zingg and Jones, 1997) . We therefore hypothesized that mutations causing loss of normal MBD4 function might lead to an increased rate of genome-wide C to T transitions, and so allow or promote tumorigenesis. MBD4 could have a tumour suppressor role similar to that for mismatch repair (MMR) genes (including MSH2, MSH3, MSH6, MLH1, PMS1, PMS2) that are mutated by nucleotide alterations or downregulated by aberrant methylation (Liu et al., 1995 (Liu et al., , 1996 Herman et al., 1998) . The presence of a translated poly-adenine tract of ten consecutive adenine nucleotides (A 10 ) within exon 3 suggested a region sensitive to mutation in microsatellite unstable (RER+) tumours (Aaltonen et al., 1993; Ionov et al., 1993; Thibodeau et al., 1993) , similar to the unstable mononucleotide tracts within a number of other genes Rampino et al., 1997; Souza et al., 1996; Malkhosyan et al., 1996) . We have therefore in this study screened the MBD4 gene for mutations in colorectal carcinomas, focusing in particular on the A 10 tract of RER+ tumours.
Fresh tumour and matching normal colon tissue samples were collected from patients with colorectal carcinoma undergoing surgery at the Royal In®rmary of Edinburgh NHS Trust. All patients had no known family history of cancer and all but two (43 and 49 years old respectively) were 60 years of age or older. Samples were stored frozen at 7708C and genomic DNA extracted from them later by standard techniques. RER+ tumours were identi®ed on the basis of microsatellite instability demonstrated at least two of ®ve interrogated sites while RER7 tumours were selected on the basis of absence of microsatellite instability at any of these sites. The tumours exhibited the histopathological features characteristic of RER+ and RER7 types as described by ourselves and others (Bubb et al., 1996; Aaltonen et al., 1993) . We screened 23 RER+ sporadic colon cancers (20 primary samples and three cell lines) across the A 10 tract by two methods. The region was polymerase chain reaction (PCR) ampli®ed and then (a) run on a 10% nondenaturing acrylamide gel under conditions suitable to detect a single base-pair dierence in length, and (b) *Correspondence: S Badercycle sequenced. We found that a total of ten (nine primary and one cell line) cases were mutated (43%), of which eight had lost one A and two had gained one A (Figure 1) , with concordance between the detection methods used. The cell line HCT116 (MLH1 mutant) was clearly heterozygous for the mutation, apparently still retaining a normal A 10 sequence in addition to an A 9 allele (Figure 1c ). Both normal and mutant alleles are expressed at the mRNA level in roughly equivalent amounts (data not shown). The status of mutations in primary tumours is more dicult to determine, as the coincidence of normal and mutated sequence might re¯ect either heterozygosity in the tumour or contamination by normal stroma of tumour with no residual normal alleles. We do, however, suspect that the primary tumours with mutations were heterozygous: the tissues analysed comprised mainly tumour yet the band intensities of mutant alleles varied from weaker than, to closely similar to, those of the wild-type alleles. Indeed, their relative intensities were often very similar to those derived from heterozygous HCT116 cells, where no stromal contamination was possible. The matching normal tissues for the mutated primary tumours did not show any alterations in the exon 3 A 10 tract, as determined by either non-denaturing gel or cycle sequencing analysis. The A 10 tract was also normal in 36 microsatellite stable (RER7) primary tumours and three RER7 colon cancer cell lines (Figure 1b,c) . This association of MBD4 A 10 tract mutations with RER+ status in sporadic colon cancers is statistically signi®cant (P50.001, w 2 test with the Yates continuity correction).
We screened the entire coding region of the gene in the 23 RER+ tumours, and in 52 RER7 tumours, by single-stranded conformation polymorphism (SSCP) assay looking for additional mutations. Genomic DNA was PCR ampli®ed for 30 cycles, each cycle being (948 30", 588 30"), in the presence of Taq polymerase (Life Technologies UK) and 33 P adATP (ICN). PCR products were run on 0.56 SequaGel MD gels (National Diagnostics) containing 10% glycerol and 0.66 TBE for 18 h at 6W at room temperature. Primers for PCR were derived from genomic sequence (Hendrich et al., 1999b) and were located just inside introns¯anking splice acceptor and donor sites of each of the seven smaller exons, or in overlapping segments along exon 3, a total of 14 primer pairs (primer sequences available from the authors upon request). We found no other mutations in any of the RER+ primary tumours or cell lines. We found only one mutation in an RER7 tumour, in exon 2 encoding the methyl-CpG binding domain (G to C, causing a glycine to alanine mis-sense change). The nucleotide dierence was also seen in normal tissue from the same patient, suggesting either a polymorphism or an inherited mutation. If it is a polymorphism, it is extremely rare as it was not seen in any of the other 74 colon patients, nor blood DNA from 110 independent normal individuals. Two authentic exonic polymorphisms were also identi®ed, one silent (C to T, cDNA nt Matched pairs of primary normal (N) and tumour (T) tissues from three RER+ cases. All three tumours carry a mutation, two with a deletion of one A, one with an insertion of one A. A 95 basepair section of exon 3 incorporating the A 10 tract was PCR ampli®ed for 30 cycles, each cycle being (948 30", 588 30"), using primers MBD4.13a (GATGCTGGAGCATGTGGT) and MBD4.12a (CAGAACAAAAATTTGATCCTGAACTC) in the presence of Pfu polymerase (Stratagene). The primer MBD4.13a was then end labelled with 33 P gdATP (ICN) using T4 polynucleotide kinase (Life Technologies UK), and used to label the original PCR products by performing two rounds of PCR using the conditions described above. Radiolabelled PCR products were diluted with non-denaturing dye and loaded onto a non-denaturing 10% acrylamide 16TBE gel, run overnight for 16 h at 10W. The gels were dried and exposed to autoradiographic ®lm. RER+ tumour, normal A 10 tissue and a mutated +1A RER+ tumour. PCR products were made using primers MBD4.11 (GATAGCAAAAGAGAATCTGTGTGTA) and MBD4.14 (CTTTCCTTTCCACAACTTCTACT), then directly sequenced with primer MBD4.36 (GTCAGCTTGATAGAACTGTCT) using Thermosequenase radio-labelled terminator cycle sequencing kits (Amersham-USB Life Sciences). Sequencing products were run on 6% acrylamide 7 M urea gels for 2 h at 80W and exposed to autoradiographic ®lm 1589) and one coding (G to A, cDNA nt 993, changing Alanine to Threonine). Both were con®rmed as natural polymorphisms, with allelic frequencies 89 and 11% in each case, upon screening blood DNAs from 110 independent, normal individuals. The MBD4 gene is therefore mutated, with one possible exception, only in sporadic colorectal cancers with the RER+ phenotype, and then only within its A 10 tract.
Our data clearly show that the gene encoding the recently described methyl-CpG binding domain protein, MBD4, is a target for frequent mutation in RER+ colorectal tumours. The mutations in our colon samples invariably involve addition or deletion of a single adenine nucleotide within the exon 3 A 10 tract, creating frameshifts that encode a premature translation stop after 12 or three altered amino acids respectively. These truncated proteins, if expressed, would lack the glycosylase domain but retain the Nterminal half of the protein including the methyl-CpG binding domain. A similar but even shorter truncation of wild-type MBD4 comprising only the methyl-CpG binding domain and lacking the glycosylase domain, has been shown still to bind methylated DNA in vitro (Hendrich et al., 1999a) . Thus, the truncated proteins of RER+ tumours would lack mismatch repair function but are expected to retain the ability to bind methylated DNA sites, whether normal or mismatched, and thus could compete with full-length MBD4 protein in a dominant negative manner.
The absence of mutations outwith the A 10 tract suggests that all the observed mutations in RER+ tumours are likely to be the result rather than the cause of defective mismatch repair. The overall incidence in our series (43%) is similar to that observed in the most labile microsatellite sites used for identi®cation of the RER+ phenotype, consistent with the view that the changes in MBD4 might merely re¯ect the presence of microsatellite instability. The incidence of mutations in MBD4 is less than that in the A 10 tract in the transforming growth factor b type II receptor (TGFbRII) gene (80%) , but close to that observed in a similar G 8 tract in the BAX gene (51%) (Rampino et al., 1997) and MSH6 (C 8 , 30%) (Malkhosyan et al., 1996) and substantially higher than in other sites including insulin-like growth factor II receptor (IGFIIR) (G 8 , 9%) (Souza et al, 1996) .
Our data, however, do not exclude the possibility of positive selection in favour of the MBD4 A 10 mutation during tumour development. If, as discussed above, such mutations exert a dominant negative eect, this would result in accumulation of mutations at methylCpG sites throughout the genome compounding the eects of MMR gene-related microsatellite instability. Furthermore, the truncated protein might exert a gain of function eect by inhibiting the binding not only of the normal MBD4 protein, but also other methyl-C binding domain-containing proteins such as MeCP2, MBD1 and MBD2. Thus, not only would G/T mismatch repair be impaired, but also normal gene regulation, through interference with repression of transcription from methylated promoter regions.
A gene with sequence identical to MBD4 has been cloned recently by another group using the yeast interaction trap system in which its protein product, via the C-terminal region, was found to bind MLH1 protein (Bellacosa et al., 1999) . Although in that report it was proposed that MBD4 has endonuclease activity, this has not been found by others (Hendrich et al., 1999a) . It was reported by Bellacosa et al. (1999) that a deletion mutant lacking the N-terminal methyl-C binding domain caused an increase in microsatellite instability due to inappropriate binding to MLH1 and an inhibition of that protein's normal repair function. It was therefore suggested that MBD4 mutations might occur in RER+ tumours that lack primary de®ciencies in MMR genes. These MBD4 mutations might inactivate the methyl-C binding function but still allow complex formation with MLH1 in a dominant negative fashion. Our data show a dierent phenomenon: mutations in MBD4 do occur in authentic, naturally occurring RER+ cases but only in the A 10 tract, truncating the protein and so removing the glycosylase and MLH1-binding domains but retaining a normal methyl-C binding domain. Mutation of the methyl-C binding domain itself as suggested does not, therefore, contribute signi®cantly to microsatellite instability in vivo because of the rarity of the necessary methyl-C binding domain mutations in RER+ tumours. It is possible that truncation of MBD4, losing the MLH1-binding domain, might further enhance the accumulation of mutations at microsatellite sequences via loss of a potential recruitment function. It is perhaps of note that the one other sequence abnormality we found in a colon tumour was a mis-sense mutation within the methyl-CpG binding domain. Were this change to impair normal methylCpG binding function of MBD4, it would mimic the mutant form created by Bellacosa et al. (1999) , and would in theory still be able to complex with MLH1 and so increase microsatellite instability. However, this does not appear to be the case since the tumour is RER7. The biological signi®cance of both the observed binding of MBD4 to MLH1 in vitro and the experimental eects of N-terminal truncated MBD4 protein on microsatellite instability thus remain to be determined.
